Cover Image
市場調查報告書

生物銀行的全球市場的預測 (2018∼2028年):醫療研究、治療目的的趨勢預測,各用途趨勢 (人體組織,幹細胞 (成體幹細胞,臍帶血) 等),主要企業,主要國家、地區分析

Biobanking Market Forecasts 2018-2028: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Stem Cells (Adult Stem Cells, Umbilical Cord), Other Applications, Leading Biobanking Companies and Key Geographies

出版商 Visiongain Ltd 商品編碼 229862
出版日期 內容資訊 英文 266 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物銀行的全球市場的預測 (2018∼2028年):醫療研究、治療目的的趨勢預測,各用途趨勢 (人體組織,幹細胞 (成體幹細胞,臍帶血) 等),主要企業,主要國家、地區分析 Biobanking Market Forecasts 2018-2028: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Stem Cells (Adult Stem Cells, Umbilical Cord), Other Applications, Leading Biobanking Companies and Key Geographies
出版日期: 2018年05月24日 內容資訊: 英文 266 Pages
簡介

全球生物銀行市場整體收益額,2023年預計達到350億美元以上。在藥物開發、醫學研究等領域的生物銀行的利用增加,及民營的生物銀行的增加等,為市場成長的主要原因。

本報告提供全球生物銀行市場相關調查分析,今後的收益預測焦點,資料,趨勢,機會,商務預測相關驗證之系統性資訊。

第1章 報告概要

第2章 生物銀行的概要和其用途

  • 人體組織銀行市場定義,和分析範圍
  • 幹細胞銀行市場 - 分類方法
  • 生物銀行是什麼?
  • 生物銀行的主要的特性
  • 所謂生物銀行包含的流程
  • 生物銀行的分類:組織的種類/志願者群組/所有者的分類模式
    • 志願者群組:一般型/特定疾病特殊化型
    • 擁有結構:官方/民營
  • 生物銀行的指南和標準
  • 生物銀行的基礎研究的法律規章
  • 生物銀行與製藥產業
    • 研究、藥物研發、藥物開發的生物銀行
      • 由於生物銀行的遺傳流行病學研究的促進
      • 疾病途徑的更佳理解為基礎,新藥的發現
      • 藥物研發過程的生物標記的發現
    • 治療過程的生物銀行
    • 臨床實驗的生物銀行

第3章 醫療用生物銀行:全球市場 (2018∼2028年)

  • 全球醫療用生物銀行市場
  • 醫療用生物銀行的預測:研究用/治療用
  • 全球醫療用生物銀行市場:整體市場收益額的預測
  • 生物銀行保管的標本數:總合15億個以上
  • 全球醫療用生物銀行市場:各部門 - 整體收益額的預測
  • 研究用生物銀行:大部分非營利
    • 市場收益額的預測
    • 比促進因素:阻礙因素都大的影響力
  • 未來的治療用生物銀行 - 私人色彩過強嗎?
    • 民營的治療用幹細胞銀行相關討論
    • 未來的治療用生物銀行:市場收益額的預測
    • 治療用生物銀行的促進、阻礙因素:未來展望

第4章 研究用生物銀行:全球市場的預測

  • 研究用生物銀行的明細:組織的各類型
  • 研究用生物銀行:未來展望 - 組織的各種類的比較
  • 研究用生物銀行 (組織的各類型):整體收益額的預測
  • 研究用生物銀行保管多少標本?
  • 研究用人體組織銀行的市場
  • 研究用人體組織銀行的市場:市場收益額的預測
  • 研究用人體組織銀行的市場:民營/公共部門
    • 民營人士體組織銀行:市場收益額的預測
    • 公共人體組織銀行:市場收益額的預測
  • 研究用幹細胞銀行市場
  • 研究用幹細胞銀行市場:市場收益額的預測
    • 愈來愈受重視向研究開發 (R&D):iPS細胞
  • 其他的研究用生物標本的銀行
  • 其他的研究用生物標本的銀行:市場收益額的預測

第5章 未來的治療用幹細胞銀行:全球市場的預測

  • 治療用幹細胞銀行:幹細胞的各種類的明細
  • 治療用幹細胞銀行,幹細胞的各類型:市場收益額、佔有率比較
  • 治療用幹細胞銀行,幹細胞的各類型:整體收益額的預測
  • 每年生物銀行保存多少幹細胞?
  • 臍帶血銀行市場
    • 民營/公共臍帶血銀行
    • 臍帶血銀行:爭議
  • 臍帶血銀行市場:收益額的預測
  • 成體幹細胞銀行市場
  • 成體幹細胞銀行市場:收益額的預測

第6章 主要國家市場預測

  • 各地區的生物銀行的分佈情形
    • 牽引歐洲:全球生物銀行網路/基礎設施
    • 美國:細分的市場
    • 亞洲:急速擴大勢力的地區
  • 醫療用生物銀行:美國先導
  • 主要國家市場:整體收益額的預測
  • 各地區市場佔有率的變動預測
  • 美國的生物銀行市場:多樣化與擴大
  • 主導歐洲主要國家的生物銀行市場:生物銀行、基礎設施的整備
    • 德國:產業的先導角色,多數團體加盟BBMRI
    • 法國:民營幹細胞銀行的法規規定市場
    • 義大利:民營幹細胞銀行
    • 英國:對生物銀行、網路的存在感的限制
    • 西班牙:民營/公共臍帶血銀行相關討論
    • 荷蘭:全面性生物銀行、網路
  • 來自日本的生物銀行市場:政府的高額投資促進成長
  • 金磚四國的生物銀行市場:成長率高,和今後的市場佔有率擴大
    • 中國:迅速的市場持續成長
    • 印度:由民營主導發展為有力市場
    • 巴西:新穎性促進市場成長,還是抑制?
    • 俄羅斯:人體組織、遺傳資訊的禁運 - 未來有可能克服嗎?

第7章 生物銀行技術:生物銀行相關的系統軟體、消耗品、服務

  • 生物銀行相關市場:概要
  • 系統技術:完全自動化處理
    • 自動液體搬運設備
    • 冷凍樣品取得 (Frozen Aliquoting):CryoXtract的專利技術
    • 自動DNA離析
  • 儲存技術:永續性,樣品追蹤的容易性,附加性安全功能
    • 乾燥、室溫保存,高價能源消費量也大的冰櫃的廢除
    • 超低溫冰櫃:利用減少嗎?
    • 冷凍保存:機器式保存 vs 液體/氣相氮式保存
    • 自動倉庫 (AS/RS):基本的技術
    • RFID和標記技術:對條碼的優點
  • 生物銀行用軟體
    • 實驗室資訊管理系統 (LIMS):僅管近來的技術進步,仍殘留未滿足需求
    • LIMS的功能
  • 消耗品:有效的抽樣管理要求的高品質性
    • 對樣品保管、追蹤的課題的應對
  • 生物銀行服務:收費的生物檢體的保管、管理、運輸

第8章 生物銀行市場主要企業

  • 生物銀行企業的各種經營模式:採購/保管
  • 民營的研究用生物銀行
    • Tissue Solutions
    • Asterand Bioscience
    • Biopta
    • BioServe
    • Coriell Institute for Medical Research
  • 代表性治療用生物銀行
    • Cord Blood America
    • Cryo-Cell International
    • Cryo-Save
    • China Cord Blood Corp
    • LifebankUSA
    • ViaCord
    • Cord Blood Registry
    • Biogenea Pharmaceuticals
    • StemLife
    • Future Health Biobank
    • Caladrius Biosciences (舊NeoStem)
    • Precious Cells

第9章 生物銀行市場定性分析

  • 產業趨勢
  • 市場優勢、弱點
  • 市場機會和威脅
  • STEP分析:對生物銀行市場的影響度

第10章 結論

用語一覽

相關分析

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0310

Biobanking - our new study reveals trends, R&D progress, and predicted revenues

Where is the Biobanking market heading? If you are involved in this sector you must read this brand-new report. Visiongain's report shows you the potential revenues streams to 2028, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 266-page report provides 145 tables, charts, clearly illustrating the data presented in this research. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted drug sales at overall world market regional level, as well as giving a deep insight into the pipeline for Biobanking. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biobanking market. See how to exploit these opportunities.

Forecasts to 2028 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2028, our new study provides you with recent results, R&D overview, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and following Biobanking Submarkets:

  • Biobanking for Research:
  • Human Tissue:
    • Commercial
    • Public
  • Stem Cells
  • Others (DNA, Blood fluids etc.)
  • Biobanking for Therapeutic Use:
  • Umbilical Cord Banking
  • Adult Stem Cell Banking

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 12 leading national markets:

  • US
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • The Netherlands
  • Japan
  • China
  • India
  • Brazil
  • Russia
  • RoW

image1

Our analysis shows activities of biobanks, including these organisations:

  • Stemgent
  • Biopta
  • BioServe
  • Coriell Institute for Medical Research
  • Cord Blood America
  • Cryo-Cell International.

And other companies, including these:

  • China Cord Blood Corp
  • LifebankUSA
  • ViaCord
  • Cord Blood Registry
  • Biogenea Pharmaceuticals
  • StemLife
  • Caladrius Biosciences.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, China, India and the US in particular, will continue to achieve high revenue growth to 2028.

Leading companies and the potential for market growth

Overall world revenue for Biobanking will surpass $35bn in 2023, our work calculates. This will be driven by the use of biobanking in drug development and medical research, as well as the expected rise in number of commercial biobanks over the forecast period

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Biobanking Market report helps you

In summary, our 266-page report provides you with the following knowledge:

  • Revenue forecasts to 2028 for the Biobanking market and Leading Submarkets - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2028 for 12 of the leading national markets - US, Germany, France, UK, Italy, Spain, Netherlands, Japan, Russia, China, India, Brazil
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market - including company profiles for 16 companies involved in commercial biobanking and biobanking for therapeutic use

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Biobanking market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Biobanking for Medicine: World Market Review 2017 and Global Segmentation
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to Biobanking and its Applications

  • 2.1 Defining the Human Tissue Banking Market for the Scope of this Report
  • 2.2 The Stem Cell Banking Market - Our Breakdown
  • 2.3 What is Biobanking?
  • 2.4 Main Features of Biobanks
  • 2.5 What Processes are Involved in Biobanking?
  • 2.6 Classification of Biobanks: Tissue Type, Volunteer Group and Ownership Classification Models
    • 2.6.1 Volunteer Group: General vs. Disease Population
    • 2.6.2 Ownership Structure: Public vs. Private
  • 2.7 The Guidelines and Standards for Biobanking
  • 2.8 Laws and Regulations for Biobank-Based Research
    • 2.8.1 HIPAA Amendments
  • 2.9 Biobanking and the Pharmaceutical Industry
    • 2.9.1 Biobanking in Research, Drug Discovery and Development
      • 2.9.1.1 Biobanking - Facilitates Genetic Epidemiology Studies
      • 2.9.1.2 Novel Drug Discovery through Better Understanding of Disease Pathways
      • 2.9.1.3 Biomarker Discovery in Drug Development
    • 2.9.2 Biobanking for Therapeutic Purposes
    • 2.9.3 Biobanking in Clinical Trials

3. Biobanking for Medicine: World Market 2018 to 2028

  • 3.1 The World Biobanking for Medicine Market in 2018
  • 3.2 Biobanking for Medicine: Research vs. Therapeutics in 2023 and 2028
  • 3.3 World Biobanking for Medicine Market: Overarching Revenue Forecast 2018 to 2028
  • 3.4 Biobanks Stored More Than 1.5 Billion Specimens in 2018
  • 3.5 The Biobanking for Medicine Market by Sector: Grouped Revenue Forecasts 2018 to 2028
  • 3.6 Biobanking for Research: Mostly Non-Profit
    • 3.6.1 Biobanking for Research: Revenue Forecast 2018 to 2028
    • 3.6.2 Driving Forces: Outweighs Restraints on the Biobanking Industry for Research
  • 3.7 Biobanking for Future Therapeutic Use: Is It Too Commercial?
    • 3.7.1 Arguments against Commercial Stem Cell Banking for Therapeutic Uses
    • 3.7.2 Biobanking for Future Therapeutic Use: Revenue Forecast 2018 to 2028
    • 3.7.3 Driving and Restraining Forces Influencing the Biobanking Market for Therapeutic Applications, 2018 to 2028

4. Biobanking for Research Purposes: World Market 2018-2028

  • 4.1 Breakdown of Biobanking for Research Market by Tissue Type, 2018
  • 4.2 Biobanking for Research in 2023 and 2028: Comparison by Tissue Type
  • 4.3 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts 2018 to 2028
  • 4.4 How Many Specimens are Biobanked for Research?
  • 4.5 The Human Tissue Banking Market for Research in 2018
  • 4.6 The Human Tissue Banking Market for Research: Revenue Forecast 2018 to 2028
  • 4.7 The Human Tissue Banking Market: Commercial vs. Public Sector
    • 4.7.1 Commercial Human Tissue Banks: Revenue Forecast 2018 to 2028
    • 4.7.2 Public Sector Human Tissue Banks: Revenue Forecast 2018 to 2028
  • 4.8 The Stem Cell Banking Market for Research in 2018
  • 4.9 The Stem Cell Banking Market for Research: Revenue Forecast 2018 to 2028
    • 4.9.1 R&D- Growing Interest Towards iPSCs
  • 4.10 Banking of Other Biologics Specimens for Research in 2018
  • 4.11 Banking of Other Biologic Specimens for Research: Revenue Forecast 2018 to 2028

5. Stem Cell Banking for Future Therapeutic Use: World Market 2018 to 2028

  • 5.1 Stem Cell Banking for Therapeutic Use in 2018: A Breakdown by Stem Cell Type
  • 5.2 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenue and Market Share, 2023 and 2028
  • 5.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts
  • 5.4 How Many Stem Cells Are Biobanked Each Year?
  • 5.5 The Umbilical Cord Blood Banking Market in 2018
    • 5.5.1 Private vs. Public Cord Blood Banking
    • 5.5.2 Umbilical Cord Blood Banking: The Controversies
  • 5.6 The Umbilical Cord Blood Banking Market: Revenue Forecast 2018 to 2028
  • 5.7 The Adult Stem Cell Banking Market in 2018
  • 5.8 The Adult Stem Cell Banking Market: Revenue Forecast 2018 to 2028

6. Leading National Markets 2018 to 2028

  • 6.1 The Geographical Footprint of Biobanking
    • 6.1.1 Biobanking in Europe: Leading the World with Biobanking Networks and Infrastructure
    • 6.1.2 Biobanks in the US: A Fragmented Picture
    • 6.1.3 Biobanking in Asia: A Region Fast Gaining Prominence
  • 6.2 Biobanking for Medicine: The US Led the Way in 2018
  • 6.3 The Leading National Markets: Grouped Revenue Forecasts 2018 to 2028
  • 6.4 How Will Regional Market Shares Change to 2028?
  • 6.5 The US Biobanking Market 2018 to 2028: Diversifying and Expanding
  • 6.6 The Top European Biobanking Markets 2018 to 2028: Leading the Way in Biobanking Infrastructure
    • 6.6.1 Germany: An Advanced Industry with 74 Biobanks Associated with the BBMRI
    • 6.6.2 France: Restrictions on Private Stem Cell Banking Limit the Market
    • 6.6.3 Italy: Is the Limited Private Stem Cell Banking Market Off-Set by Strong Biobanking Networks for Research?
    • 6.6.4 UK: Limited Presence of Biobanking Networks
    • 6.6.5 Spain: Controversy Between Private and Public Umbilical Cord Blood Banks
    • 6.6.6 The Netherlands is Characterised by Comprehensive Biobanking Networks
  • 6.7 The Japanese Biobanking Market 2018 to 2028: A High Level of Government Investment Drives Growth
  • 6.8 The Biobanking Industry in the BRIC Countries: High Growth and Increasing Market Share between 2018 and 2028
    • 6.8.1 The Chinese Biobanking Market 2018 to 2028: The High Rate of Growth Will Continue
    • 6.8.2 The Indian Biobanking Market 2018 to 2028: Set to Become the Leading Market for Private Stem Cell Banking?
    • 6.8.3 The Brazilian Biobanking Market 2018 to 2028: Will New Regulations Drive or Restrain the Market?
    • 6.8.4 Russia: Ban on the Import and Export of Human Tissue and Genetic Information Restricts the Market, But Can This Be Overcome from 2018 to 2028?

7. Technology for Biobanking: Systems, Software, Consumables, and Services Associated with Biobanking

  • 7.1 The Biobanking-Associated Market: Overview
  • 7.2 Systems Technology: Fully Automated Handling
    • 7.2.1 Automated Liquid Handling Systems
    • 7.2.2 Frozen Aliquoting: Patented Technology from CryoXtract
    • 7.2.3 Automated DNA Isolation
  • 7.3 Storage Technology: Sustainability, Easy Sample Tracking, and Added Security
    • 7.3.1 Dry State, Room Temperature Storage Eliminates the Need for Expensive, Energy-Consuming Freezers
    • 7.3.2 Ultra-Low Temperature Freezers: Is Their Use Declining?
    • 7.3.3 Cryopreservation: Mechanical vs. Liquid/ Vapour Phase Nitrogen
    • 7.3.4 Automated Storage and Retrieval Systems: Essential Technology
    • 7.3.5 RFID and Tagging Technology: Advantages over Barcodes
  • 7.4 Software for Biobanks
    • 7.4.1 Laboratory Information Management System (LIMS): Unmet Needs in the Market Remain, Despite Recent Advances
    • 7.4.2 LIMS Functions
  • 7.5 Consumables: High Quality Required for Effective Sample Management
    • 7.5.1 Addressing Sample Storage and Tracking Issues
  • 7.6 Biobanking Services: Storage, Management and Transport of Biologic Samples for a Fee

8. Leading Companies in the Biobanking Market, 2017

  • 8.1 The Differing Business Models of Biobanking Companies: Sourcing vs. Storing
  • 8.2 Commercial Biobanks for Research Purposes in 2018
    • 8.2.1 Tissue Solutions: A Virtual Biobank with a Global Presence
      • 8.2.1.1 An Overview of the Products and Services Offered by Tissue Solutions
      • 8.2.1.2 Banked Samples Occur in Many Formats
      • 8.2.1.3 Prospective Tissue Collection for Hard-to-Find Samples
      • 8.2.1.4 Fresh Samples from Surgical Resections are in High Demand
      • 8.2.1.5 Freshly Isolated Human Cells are a Valuable Research Tool
      • 8.2.1.6 FDA/EMA Panel of Normal Tissues
      • 8.2.1.7 Strengths, Capabilities and the Future Outlook for Tissue Solutions
    • 8.2.2 Asterand Bioscience is now Part of Stemgent
      • 8.2.2.1 Asterand's Products and Services: XpressBANK, BioSpoke and PhaseZERO
      • 8.2.2.2 The Future Outlook for Asterand
    • 8.2.3 Biopta: Human Tissue Provider Now Acquired by Japanese Company ReproCELL
      • 8.2.3.1 Services from Biopta: A Variety of Lab Services and Fresh Tissue Sample Procurement
      • 8.2.3.2 The First Catalogue of Assays Based on Human Functional Tissues
      • 8.2.3.3 The Future Outlook for Biopta: Fresh Tissue Will Be in Demand
    • 8.2.4 BioServe: One of the World's Largest Commercial Biorepositories
      • 8.2.4.1 BioServe Offers a Comprehensive List of Services: Biobanking, Sourcing and Preclinical Molecular Services
      • 8.2.4.2 The Future Outlook for BioServe
    • 8.2.5 Coriell Institute for Medical Research: Reportedly the Largest Biobank in the World
      • 8.2.5.1 Features of and Recent Developments at Coriell Biobank
      • 8.2.5.2 Future Outlook for the Coriell Biobank
  • 8.3 Prominent Biobanks for Therapeutic Use in 2018
    • 8.3.1 Cord Blood America: Expansion into the Emerging Markets Apparently Stalled, Strategic Alternatives Being Considered
    • 8.3.2 Cryo-Cell International: The First Private Cord Blood Bank in the Market
    • 8.3.3 Cryo-Save's Educational Programme Benefits Company's Growth
    • 8.3.4 China Cord Blood Corp: The Only Cord Blood Bank in China with Multiple Licences Is Under a New Owner
    • 8.3.5 LifebankUSA: Acquisition from Human Longevity Inc Will Potentially Drive Growth
    • 8.3.6 ViaCord: More Blood Units Released for Therapy than Any Other Family Bank
    • 8.3.7 Cord Blood Registry: The World's Largest Newborn Stem Cell Company Will Be Promoted By New Parent Company
    • 8.3.8 Biogenea Pharmaceuticals: A Comprehensive Offering of Stem Cell Banking Services across the Balkan Peninsula
    • 8.3.9 StemLife is Reportedly Facing Challenges due to Government Regulations in Malaysia
    • 8.3.10 Future Health Biobank: A Strong Market Presence Owing to International Operations
    • 8.3.11 Caladrius Biosciences (formerly NeoStem): More Focus on Cell Therapy Than Stem Cell Banking
    • 8.3.12 Precious Cells is Well Positioned to Take Advantage of the Growing Demand in India

9. Qualitative Analysis of the Biobanking Market 2018 to 2028

  • 9.1 Industry Trends
    • 9.1.1 The Growing Demand for Biobank Resources for Research
    • 9.1.2 The Establishment of Biobanking Networks
      • 9.1.2.1 BBMRI: The Most Extensive Biobank Network
    • 9.1.3 Virtual Biobanks: Connecting a Fragmented Industry
    • 9.1.4 Commercial Biobanks as Intermediaries: New Resources for Research
    • 9.1.5 Automated Biobanking Has Become Imperative
    • 9.1.6 Increasing Uptake of LIMS
    • 9.1.7 Green Banking - Becoming More Energy Efficient
  • 9.2 The Strengths and Weaknesses of the Biobanking Market in 2017
    • 9.2.1 HBS are Valuable Resources for R&D
    • 9.2.2 Governmental Support for Biobanking Forms a Strength of that Industry
    • 9.2.3 Development of Potential Novel Stem Cell Therapies has Increased Public Awareness of Stem Cell Banking
    • 9.2.4 The Effect of Big Data on Biobanking
    • 9.2.5 Insufficient Accessible Numbers of High Quality Biospecimens
    • 9.2.6 Biobanks are Fragmented and Uncoordinated
    • 9.2.7 Lack of Standardisation is a Weakness of the Industry
    • 9.2.8 Lack of Public Awareness Limits Number of Donors
    • 9.2.9 Lack of Engagement with Public Health Services Limits the Stem Cell Banking Market
  • 9.3 Opportunities and Threats Facing the Biobanking Market, 2018 to 2028
    • 9.3.1 Increasing Use of Biobanked Specimens in Genome-Wide Association Studies (GWAS)
    • 9.3.2 Increasing Demand for Biobanked Samples for Preclinical Research
    • 9.3.3 Biobanking Networks as a Basis for Personalised Medicine
    • 9.3.4 Options for Adult Stem Cell Banking Mean an Increasing Target Population for Private Stem Cell Banks
    • 9.3.5 Even With Governmental Funding, Biobanks Must Become Self-Sufficient to Thrive Long-Term
    • 9.3.6 Public Concerns over Confidentiality and Security Threaten Availability of Donors
    • 9.3.7 Limitations Surrounding Informed Consent
  • 9.4 Social, Technological, Economic and Political Factors (STEP) Influencing the Biobanking Industry, 2018 to 2028

10. Conclusions

  • 10.1 World Biobanking Market 2018 to 2028: High Revenue Growth Predicted
  • 10.2 Biobanking for Research 2018 to 2028: The Value of Biobanked Specimens is Increasingly Recognised
  • 10.3 Biobanking for Therapeutic Use 2018 to 2028: Rapid Expansion in Adult Stem Cell Banking
  • 10.4 The Leading National Markets: High Sales Growth Worldwide
  • 10.5 Current and Future Trends in Biobanking
    • 10.5.1 Increasing Demand for Biobanked Samples - Increasing Revenue
    • 10.5.2 Improving Biobanking Infrastructure - Growth Driver and a Need for Strategic Planning for Sustainability
    • 10.5.3 Marked Challenges, but Opportunities for Expansion
  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

Table of Tables

  • Table 1.1 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2018 to 2028 (redacted)
  • Table 2.1 Prominent Population-Based Biobanks, 2018
  • Table 2.2 Prominent Disease-Based Biobanks, 2018
  • Table 2.3 Guidelines and Recommendations for Biobanks, 2018
  • Table 2.4 Laws and Other Regulations for Biobank-Based Research by Country/ Organisation 2018
  • Table 2.5 Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2018
  • Table 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($bn) and Market Share (%), 2018
  • Table 3.2 Biobanking for Medicine: Research vs. Therapeutics in 2023 and 2028
  • Table 3.3 Biobanking for Medicine: Overall World Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 3.4 The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast No. Of Samples (Bn), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 3.5 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 3.6 Biobanking Market for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 3.7 Biobanking for Therapeutic Use Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 4.1 The Biobanking for Research Market by Tissue Type: Revenues ($bn) and Market Shares (%), 2018
  • Table 4.2 Biobanking for Research by Tissue Type: A Comparison of Revenues ($bn) and Market Shares (%), 2023 and 2028
  • Table 4.3 Biobanking for Research by Tissue Type: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 4.4 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 4.5 The Human Tissue Banking Market Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 4.6 The Commercial vs. Public Sector Human Tissue Banking Market: Comparison of Revenues ($bn) and Market Share (%), 2018, 2023 and 2028
  • Table 4.7 Commercial Human Tissue Banking Forecast, Revenue ($bn) Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 4.8 Commercial Human Tissue Banking Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 4.9 Prominent Commercial Human Tissue Banks, 2018
  • Table 4.10 Public Sector Human Tissue Banking Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 4.11 Prominent Public-Funded Human Tissue Banks, 2018
  • Table 4.12 The Stem Cell Banking Market for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 4.13 Prominent Stem Cell Banks Serving the Research Community, 2018
  • Table 4.14 Banking of Other Biologic Specimens for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 4.15 Prominent Biobanks Storing Other Biologic Samples, 2018
  • Table 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Share (%), 2018
  • Table 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn) and Market Share (%), 2023 and 2028
  • Table 5.3 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 5.4 The Number of Stem Cell Samples Banked for Therapeutic Use: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 5.5 Prominent Public and Private Cord Blood Banks, 2018
  • Table 5.6 The Umbilical Cord Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2018
  • Table 5.7 Prominent Companies in the Adult Stem Cell Banking Industry, 2018
  • Table 5.8 The Adult Stem Cell Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.1 Breakdown of BBMRI Network Directory Members by Country, 2018
  • Table 6.2 The Leading National Biobanking Markets: Comparison of Revenues ($bn) and Market Shares (%), 2018
  • Table 6.3 Leading National Markets Grouped Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.4 Leading National Markets: Comparison of Market Share (%), 2018, 2023 and 2028
  • Table 6.5 Biobanking for Medicine in the US Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.6 The Leading European Markets for Biobanking Grouped Forecasts: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.7 Examples of Biobanking Initiatives Funded by the European Commission, 2018
  • Table 6.8 The German Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.9 The French Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.10 The Italian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.11 The United Kingdom Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.12 The Spanish Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.13 Prominent Clinical and Population Biobanks in the Netherlands, 2018
  • Table 6.14 The Netherlands Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.15 The Japanese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.17 The Chinese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.18 The Indian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.19 Prominent Research Biobanks in India, 2018
  • Table 6.20 The Brazilian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 6.21 The Russian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2028
  • Table 7.1 Prominent Companies Providing Automated Liquid Handling Technology, 2017
  • Table 7.2 Prominent Companies Providing Room Temperature Storage Solutions, 2018
  • Table 7.3 Prominent Companies Providing Ultra-Low Temperature Freezers (-80°C), 2017
  • Table 7.4 Mechanical Freezing vs. Liquid Nitrogen: Comparison of Advantages and Disadvantages, 2017
  • Table 7.5 Prominent Companies Providing Cryogenic Storage Solutions, 2017
  • Table 7.6 Prominent Providers of Automated Biobanking Systems, 2017
  • Table 7.7 Major Vendors in the LIMS Market, 2017
  • Table 7.8 Prominent Vendors of Consumables for Biobanking, 2018
  • Table 7.9 Prominent Biorepository Service Providers, 2018
  • Table 8.1 Prominent Players in the Biobanking Industry for Research, 2018
  • Table 8.2 Prominent Companies in the Stem Cell Banking Industry for Therapeutic Use, 2018
  • Table 8.3 China Cord Blood Corp: Revenue ($m), Total Units Stored for Subscribers, and No. Of New Subscribers, 2014 to 2016
  • Table 8.4 StemLife: Comparison of Revenue ($m) between 2015 and 2016
  • Table 9.1 Strengths and Weaknesses of the Biobanking Industry, 2018
  • Table 9.2 Opportunities and Threats Facing the Biobanking Industry, 2017 to 2028
  • Table 9.3 Social, Technological, Economic and Political (STEP) Forces Influencing the Biobanking Industry, 2017 to 2028

Table of Figures

  • Figure 1.1 Global Biobanking Industry Segmentation Overview, 2018
  • Figure 2.1 Processes Involved in Biobanking, 2018
  • Figure 2.2 The Classification of Biobanks, 2018
  • Figure 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($bn) and Market Share (%), 2018
  • Figure 3.2 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2023
  • Figure 3.3 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2028
  • Figure 3.4 Biobanking for Medicine: Overarching Revenue Forecast ($bn), 2018 to 2028
  • Figure 3.5 The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast, No. of Samples (m), 2017 to 2028
  • Figure 3.6 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), 2018 to 2028
  • Figure 3.7 Biobanking Market for Research: Revenue Forecast ($bn), 2018 to 2028
  • Figure 3.8 Biobanking for Research: Drivers and Restraints, 2018 to 2028
  • Figure 3.9 Biobanking for Therapeutic Use: Revenue Forecast ($bn), 2018 to 2028
  • Figure 3.10 Biobanking for Therapeutic Use: Drivers and Restraints, 2018 to 2028
  • Figure 4.1 The Biobanking for Research Market by Tissue Type: Market Share (%), 2018
  • Figure 4.2 Biobanking for Research by Tissue Type: Market Shares (%), 2023
  • Figure 4.3 Biobanking for Research by Tissue Type: Market Shares (%), 2028
  • Figure 4.4 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts ($bn), 2018 to 2028
  • Figure 4.5 Biobanking for Research: Market Drivers and Restraints, 2018 to 2028
  • Figure 4.6 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), 2018 to 2028
  • Figure 4.7 The Human Tissue Banking Market: Revenue Forecast ($bn), 2018 to 2028
  • Figure 4.8 Human Tissue Banking for Research: Market Drivers and Restraints, 2018 to 2028
  • Figure 4.9 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2018
  • Figure 4.10 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2023
  • Figure 4.11 The Commercial vs. Public Sector Human Tissue Banking Market: Market Share (%), 2028
  • Figure 4.12 The Human Tissue Banking Market by Subsector: Revenue Forecasts ($bn), 2018 to 2028
  • Figure 4.13 Commercial Human Tissue Banking: Revenue Forecast ($bn), 2018 to 2028
  • Figure 4.14 Public Sector Human Tissue Banking: Revenue Forecast ($bn), 2018 to 2028
  • Figure 4.15 The Stem Cell Banking Market for Research: Revenue Forecast ($bn), 2018 to 2028
  • Figure 4.16 Stem Cell Banking for Research: Market Drivers and Restraints, 2018 to 2028
  • Figure 4.17 Banking of Other Biologic Specimens for Research: Revenue Forecast ($bn), 2018 to 2028
  • Figure 4.18 Biobanking of Other Biologic Specimens for Research: Market Drivers and Restraints, 2018 to 2028
  • Figure 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2018
  • Figure 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2023
  • Figure 5.3 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2028
  • Figure 5.4 Biobanking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts ($bn), 2018 to 2028
  • Figure 5.5 The Number of Stem Cell Samples Banked for Therapeutic Use (m): Forecast 2018 to 2028
  • Figure 5.6 The Stem Cell Banking Market for Future Therapeutic Use: Drivers and Restraints, 2018 to 2028
  • Figure 5.7 The Umbilical Cord Banking Market: Revenue Forecast ($bn), 2018 to 2028
  • Figure 5.8 The Umbilical Cord Blood Banking Market: Drivers and Restraints, 2018 to 2028
  • Figure 5.9 The Adult Stem Cell Banking Market: Revenue Forecast ($bn), 2018 to 2028
  • Figure 5.10 The Adult Stem Cell Banking Market: Drivers and Restraints, 2018 to 2028
  • Figure 6.1 The Leading National Biobanking Markets: Market Shares (%), 2018
  • Figure 6.2 The Leading National Markets: Grouped Revenue Forecasts ($bn), 2018 to 2028
  • Figure 6.3 The Leading National Markets: Market Share (%), 2023
  • Figure 6.4 The Leading National Markets: Market Share (%), 2028
  • Figure 6.5 Biobanking for Medicine in the US: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.6 Driving and Restraining Factors of the US Biobanking Market, 2018 to 2028
  • Figure 6.7 The Leading European Markets for Biobanking: Grouped Revenue Forecasts ($bn), 2018 to 2028
  • Figure 6.8 Biobanking in the Leading European Countries: Driving and Restraining Factors, 2018 to 2028
  • Figure 6.9 The German Biobanking Industry: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.10 The French Biobanking Industry: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.11 The Italian Biobanking Industry: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.12 The UK Biobanking Industry: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.13 The Spanish Biobanking Industry: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.14 The Netherlands Biobanking Industry: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.15 The Japanese Biobanking Industry: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.16 Driving and Restraining Factors Influencing the Japanese Biobanking Industry, 2018 to 2028
  • Figure 6.17 The Biobanking Industry in the BRIC Countries: Grouped Revenue Forecasts ($bn), 2018 to 2028
  • Figure 6.18 Driving and Restraining Factors of the Biobanking Industry in the BRIC Countries, 2018 to 2028
  • Figure 6.19 The Chinese Biobanking Industry: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.20 The Indian Biobanking Industry: Revenue ($bn) Forecast, 2018 to 2028
  • Figure 6.21 The Brazilian Biobanking Market: Revenue Forecast ($bn), 2018 to 2028
  • Figure 6.22 The Russian Biobanking Industry: Revenue Forecast ($bn), 2018 to 2028
  • Figure 7.1 Structure of the Biobanking Industry: Biobanking-Associated Market, Biobanks and End Users, 2017
  • Figure 7.2 The Basic Function of LIMS
  • Figure 8.1 Biobanking Business Model: Commercial Sourcing of Biological Samples, 2018
  • Figure 8.2 Business Model: Commercial Banking of Biological Samples

COMPANIES LISTED

  • Abbott Laboratories
  • AKH Biobank
  • AllCells
  • American CryoStem
  • American Type Culture Collection
  • Analytical Biological Services
  • ARUP Laboratories
  • ASPREE Healthy Ageing Biobank
  • Assure Immune
  • Asterand
  • AstraZeneca
  • Aurora Biomed
  • Auto scribe Informatics
  • Bangalore Brain Bank
  • Barts Gynae Tissue Bank
  • Bayer
  • BBMRI
  • Beckman Coulter
  • BINDER
  • Bio Fortis
  • Bio Life Solutions
  • Bio Repository Resources
  • BioCision
  • Biogenea
  • Biomatrica
  • Biopta
  • BioreclamationIVT
  • BioRep
  • BioServe Biotechnologies
  • BioSHARE
  • Biovault Technical
  • BIOVIA
  • BrainNet Europe
  • Bristol-Myers Squibb
  • Brooks Automation (acquired Bio Storage Technologies)
  • Brooks Life Science Systems
  • Caladrius Biosciences
  • Cambridge Biomedical Research Centre
  • Cancer Genetics Inc
  • CARTaGENE
  • CCLG Tissue Bank
  • Cells4Life
  • Celltex Therapeutics
  • Cellular Dynamics International Inc
  • Cesca Therapeutics
  • China Cord Blood Corp.
  • China Kadoorie Biobank
  • CLB/Amsterdam Medical Center
  • CMD Biobank
  • CONCOR
  • CorCell
  • Cord Blood America
  • Cord Life
  • CORE Informatics
  • Coriell Institute for Medical Research
  • Cryo Bio System
  • Cryo-Cell
  • Cryo-Cell International
  • Cryogene Lab
  • CryoLogic
  • Cryo-Save
  • Cureline
  • Custom Biogenic Systems
  • Cybrdi
  • DeCODE Genetics (Amgen)
  • Eli Lilly
  • Eli Lilly
  • ENGAGE
  • Eppendorf
  • Esco
  • ESFRI
  • Fisher Bio Services
  • FluidX
  • Future Health Biobank
  • GE Healthcare SeqWright Genomic Services
  • GEN2PHEN
  • Gilson
  • GlaxoSmithKline
  • Haier Biomedical
  • Hamilton Robotics
  • Hamilton Storage Technologies
  • Hospital Necker Paris
  • Hudson Robotics
  • Human Longevity Inc
  • Hungarian Biobank
  • Huntington Disease Biobank
  • In biomed
  • Indivumed
  • Infectious Disease Biobank
  • IntegenX
  • International Stem Cell Corporation
  • Kaiser Permanente
  • King's College London Tissue Bank
  • Lab ware
  • LABVANTAGE
  • Leiden Longevity
  • Leiden University Medical Center
  • Life Bank USA
  • Life Gene
  • Life Lines Biobank
  • Malmö Microbiology Biobank
  • Merck
  • Micronics
  • Mitochondrial Disease Biobank
  • NESDA
  • Novare Biologistics
  • Novartis
  • Ocimum Bio solutions
  • OnCore UK
  • Organisation for Economic Co-operation and Development (OECD)
  • OriGene
  • Pacific Bio Storage
  • PALGA
  • Panasonic Biomedical
  • Parelsnoer
  • PerkinElmer
  • Pfizer
  • Pharma Cells
  • Pop-Gen National Cohort
  • Precious Cells
  • Precision Bio services
  • PrecisionMed
  • PREVEND
  • Progenicyte
  • ProMedDx
  • ProteoGenex
  • Qiagen
  • Riken BRC Cell Bank
  • Roche
  • Sapien Biosciences
  • Scéil
  • Smart Cells
  • StarLIMS
  • Steelgate
  • Stem Life
  • Stem Save
  • Stemcyte
  • System Biosciences
  • Taiyo Nippon Sanso
  • TAP Bio systems (now owned by Sartorius Stedim Biotech)
  • TCG Life Sciences Tissue Bank
  • Tecan
  • Thermo Fisher Scientific
  • TISS-EU Project
  • Tissue Solutions
  • TTP Labtech
  • UCL Biobank
  • US Biomax
  • Via Cord
  • Virgin Health Bank

List of Organisations Mentioned

  • Chernobyl Tissue Bank
  • Cord Blood Registry (CBR)
  • Estonian Genome Project
  • Food and Drugs Administration (FDA)
  • Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • H. Lee Moffitt Cancer Center and Research Institute
  • Harvard Stem Cell Institute
  • Imperial Tissue Bank
  • Japanese Ministry of Health, Labour and Welfare
  • Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center
  • National Genome Research Network (NGFN)
  • National Institute of Standards and Technology (NIST)cel
  • National Institutes of Biomedical Innovation, Health and Nutrition (NIBHN)
  • National Institutes of General Medical Sciences
  • Netherlands Twin Registry
  • NHS
  • NHS Blood and Transplant Cord Blood Bank
  • NICE
  • Russian Ministry of Health
  • Russian Society for Biobanking and Biopreservation (RSBB)
  • Russian Society of Personalised Medicine (RSPM)
  • Singapore Cord Blood Bank
  • Stanford Tissue Bank
  • Swedish Institute for Infectious Disease Control Biobank
  • Tata Memorial Hospital Tissue Bank
  • The Cambridge Brain Bank
  • The Guangzhou Biobank
  • The National Cancer Tissue Bank, Indian Institute of Technology
  • UK Biobank
  • UK ME-CFS Biobank
  • UK Multiple Sclerosis Tissue Bank
  • UK Parkinson's Disease Tissue Bank
  • UK Stem Cell Bank
  • University of Tüebingen
  • World Health Organisation (WHO)
  • Wisconsin International Stem Cell Bank
Back to Top